This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Warren, D. J. Articles by Slørdal, L. Search for Related Content PubMed PubMed Citation Articles by Warren, D. J. Articles by Slørdal, L.

Quantitation of 6-Thioguanine Residues in Peripheral Blood Leukocyte DNA Obtained from Patients Receiving 6-Mercaptopurine-based Maintenance Therapy¹

Department of Clinical Pharmacology, The Norwegian Radium Hospital, Montebello, N-0310 Oslo, Norway

The antimetabolite 6-mercaptopurine is widely utilized in maintenance therapy for childhood acute lymphoblastic leukemia. Following p.o. administration, this prodrug undergoes extensive biotransformation, resulting in the generation of a plethora of metabolites including 2'-deoxy-6-thioguanosine triphosphate. Incorporation of 6-thioguanine (6-TG) bases into DNA is generally considered to be central to thiopurine-mediated cytotoxicity. We have developed a novel precolumn derivatization HPLC technique for quantifying 6-TG base accumulation into leukocyte DNA obtained from acute lymphoblastic leukemia patients receiving 6-mercaptopurine maintenance therapy. The method is based on enzymatic degradation of DNA to 2'-deoxyribonucleosides and the derivatization of released 2'-deoxy-6-thioguanosine with a thiol-reactive reagent containing a 7-amino-4-methylcoumarin-3-acetic acid fluorophore. The 2'-deoxy-6-thioguanosine-7-amino-4-methylcoumarin-3-acetic acid adduct is resolved by reversed-phase HPLC and quantified fluorometrically. Assay response is linear from 15 pmol to 60 fmol 6-TG bases/µg DNA with a limit of quantitation corresponding to the incorporation of 1 6-TG residue per 50,000 bases. In a small cohort of acute lymphoblastic leukemia patients receiving p.o. 6-mercaptopurine-based maintenance therapy, significant interindividual variation in the accumulation of 6-TG bases into leukocyte DNA was revealed. The determined levels of drug base incorporation ranged from 95 to 710 fmol 6-TG bases/µg DNA (6-TG base:nucleotide ratio 1:32,000 to 1:4,000). The assay may provide a novel methodology for pharmacological monitoring of thiopurine therapy either in the routine clinical setting or during studies of alternative routes of drug delivery.

¹ This work was supported by grants from the Norwegian Cancer Society and the Käte Forsberg Legacy. D. J. W. is a Norwegian Cancer Society Senior Researcher.

² To whom requests for reprints should be addressed.

Received 12/21/94. Accepted 3/ 6/95.

This article has been cited by other articles:

				C. Gu and Y. Wang In vitro replication and thermodynamic studies of methylation and oxidation modifications of 6-thioguanine Nucleic Acids Res., June 28, 2007; 35(11): 3693 - 3704. [Abstract] [Full Text] [PDF]

				P. Karran Thiopurines, DNA damage, DNA repair and therapy-related cancer Br. Med. Bull., February 2, 2007; (2007) ldl020v1. [Abstract] [Full Text] [PDF]

				P. O'Donovan, C. M. Perrett, X. Zhang, B. Montaner, Y.-Z. Xu, C. A. Harwood, J. M. McGregor, S. L. Walker, F. Hanaoka, and P. Karran Azathioprine and UVA Light Generate Mutagenic Oxidative DNA Damage Science, September 16, 2005; 309(5742): 1871 - 1874. [Abstract] [Full Text] [PDF]

				G. Zaza, M. Cheok, W. Yang, J. C. Panetta, C.-H. Pui, M. V. Relling, and W. E. Evans Gene expression and thioguanine nucleotide disposition in acute lymphoblastic leukemia after in vivo mercaptopurine treatment Blood, September 1, 2005; 106(5): 1778 - 1785. [Abstract] [Full Text] [PDF]

				L. Somerville, E. Y. Krynetski, N. F. Krynetskaia, R. D. Beger, W. Zhang, C. A. Marhefka, W. E. Evans, and R. W. Kriwacki Structure and Dynamics of Thioguanine-modified Duplex DNA J. Biol. Chem., January 3, 2003; 278(2): 1005 - 1011. [Abstract] [Full Text] [PDF]

				S. A. Coulthard, L. A. Hogarth, M. Little, E. C. Matheson, C. P. F. Redfern, L. Minto, and A. G. Hall The Effect of Thiopurine Methyltransferase Expression on Sensitivity to Thiopurine Drugs Mol. Pharmacol., July 1, 2002; 62(1): 102 - 109. [Abstract] [Full Text] [PDF]

				T. Dervieux, Y. Chu, Y. Su, C.-H. Pui, W. E. Evans, and M. V. Relling HPLC Determination of Thiopurine Nucleosides and Nucleotides in Vivo in Lymphoblasts following Mercaptopurine Therapy Clin. Chem., January 1, 2002; 48(1): 61 - 68. [Abstract] [Full Text] [PDF]

				N. F. KRYNETSKAIA, X. CAI, J. L. NITISS, E. Y. KRYNETSKI, and M. V. RELLING Thioguanine substitution alters DNA cleavage mediated by topoisomerase II FASEB J, November 1, 2000; 14(14): 2339 - 2344. [Abstract] [Full Text]

				N. F. Krynetskaia, E. Y. Krynetski, and W. E. Evans Human RNase H-Mediated RNA Cleavage from DNA-RNA Duplexes Is Inhibited by 6-Deoxythioguanosine Incorporation into DNA Mol. Pharmacol., October 1, 1999; 56(4): 841 - 848. [Abstract] [Full Text]